Overview

MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
0
Participant gender:
All
Summary
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Cale Jacobs, PhD
University of Kentucky
Collaborators:
Duke University
The Cleveland Clinic
University of California, San Francisco
Treatments:
Montelukast
Criteria
Inclusion Criteria:

1. Undergoing primary ACL reconstruction

2. Age between 25-50

3. Concomitant meniscus injury

Exclusion Criteria:

1. Undergoing revision procedures

2. Multiple ligament injuries requiring multiple ligament reconstruction/repair

3. Depressive symptoms and/or those who endorse suicidal ideation at the time of
enrollment (PHQ-9 score >= 15)

4. Found to not have a meniscus tear at the time of surgery